ALETA CABUHAT: Open Payments
NPI 1386069060 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$943 in 42 payments from 16 companies in 2025. Trend: 2023 $2,130 · 2024 $1,079 · 2025 $943
Food & beverage: $943
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $159 |
| ABIOMED | 1 | $144 |
| PFIZER INC. | 6 | $128 |
| SCPHARMACEUTICALS INC. | 5 | $77 |
| Novartis Pharmaceuticals Corporation | 4 | $70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $61 |
| E.R. Squibb & Sons, L.L.C. | 2 | $49 |
| BridgeBio Pharma, Inc. | 2 | $38 |
| Merck Sharp & Dohme LLC | 2 | $35 |
Products named: VYNDAQEL, FUROSCIX, LOKELMA, WAINUA, LEQVIO, JARDIANCE, Kerendia, CAMZYOS.
Industry payments across NY — which companies pay providers there.
